Does PSADT After Radical Prostatectomy Correlate with Overall Survival?--a Report from the SEARCH Database Group

Overview

Journal Urology

Specialty Urology

Date 2010 Dec 15

PMID 21145094

Citations 9

Authors

Anna E Teeter

Joseph C Presti Jr

William J Aronson

Martha K Terris

Christopher J Kane

Christopher L Amling

Stephen J Freedland

Affiliations

Soon will be listed here.

Abstract

Objectives: To examine the correlation between the prostate-specific antigen doubling time (PSADT) and overall survival (OS) and among men in the SEARCH database (an older, racially diverse cohort undergoing RP at multiple Veterans Affairs medical centers). Previous studies largely performed at tertiary care centers with relatively young, racially homogenous cohorts found a short PSADT on recurrence after RP portended a poor prognosis.

Methods: We performed a Cox proportional hazards analysis to examine the correlation between postrecurrence PSADT and the interval from recurrence to OS and prostate cancer-specific mortality among 345 men in the SEARCH database who had undergone RP from 1988 to 2008. We examined the PSADT as a categorical variable using the clinically significant cutpoints of <3, 3-8.9, 9-14.9, and ≥15 months.

Results: A PSADT of <3 months (hazard ratio 5.48, P = .002) was associated with poorer OS than a PSADT of ≥15 months. A trend was seen toward worse OS for the men with a PSADT of 3-8.9 months (hazard ratio 1.70, P = .07). PSADTs of <3 months (P < .001) and 3-8.9 months (P = .004) were associated with an increased risk of prostate cancer-specific mortality.

Conclusions: In an older, racially diverse cohort, recurrence with a PSADT of <9 months was associated with worse all-cause mortality. The results of the present study have validated previous findings that PSADT is a useful tool for identifying men at increased risk of all-cause mortality early in their disease course.

Citing Articles

Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate.

Li X, Xi H, Cheng X, Yu Y, Zhang C, Wang G Front Endocrinol (Lausanne). 2023; 14:1123934.

PMID: 36843605 PMC: 9951113. DOI: 10.3389/fendo.2023.1123934.

CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.

Shore N, Morrow M, McMullan T, Kraynyak K, Sylvester A, Bhatt K Mol Ther. 2020; 28(5):1238-1250.

PMID: 32208168 PMC: 7210698. DOI: 10.1016/j.ymthe.2020.02.018.

Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.

Howard L, Moreira D, de Hoedt A, Aronson W, Kane C, Amling C BJU Int. 2017; 120(5B):E80-E86.

PMID: 28371163 PMC: 5617753. DOI: 10.1111/bju.13856.

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.

Jochems C, Tucker J, Tsang K, Madan R, Dahut W, Liewehr D Cancer Immunol Immunother. 2014; 63(4):407-18.

PMID: 24514956 PMC: 6314199. DOI: 10.1007/s00262-014-1524-0.

A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.

Jackson W, Johnson S, Li D, Foster C, Foster B, Song Y Radiat Oncol. 2013; 8:170.

PMID: 23835115 PMC: 3718717. DOI: 10.1186/1748-717X-8-170.

References

Grossfeld G, Latini D, Downs T, Lubeck D, Mehta S, Carroll P . Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?. J Urol. 2002; 168(6):2510-5. DOI: 10.1016/S0022-5347(05)64179-1. View

Moreira D, Antonelli J, Presti Jr J, Aronson W, Terris M, Kane C . Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2010; 76(5):1218-23. PMC: 3177236. DOI: 10.1016/j.urology.2010.01.066. View

Lee A, Levy L, Cheung R, Kuban D . Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys. 2005; 63(2):456-62. DOI: 10.1016/j.ijrobp.2005.03.008. View

Ward J, Zincke H, Bergstralh E, Slezak J, Blute M . Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004; 172(6 Pt 1):2244-8. DOI: 10.1097/01.ju.0000145262.34748.2b. View

DAmico A, Moul J, Carroll P, Sun L, Lubeck D, Chen M . Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003; 95(18):1376-83. DOI: 10.1093/jnci/djg043. View

Albertsen P, Hanley J, Penson D, Fine J . Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol. 2004; 171(6 Pt 1):2221-5. DOI: 10.1097/01.ju.0000124381.93689.b4. View

Pound C, Partin A, Eisenberger M, Chan D, Pearson J, Walsh P . Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281(17):1591-7. DOI: 10.1001/jama.281.17.1591. View

Moreira D, Banez L, Presti Jr J, Aronson W, Terris M, Kane C . Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2009; 105(1):28-33. DOI: 10.1111/j.1464-410X.2009.08684.x. View

Jayachandran J, Aronson W, Terris M, Presti Jr J, Amling C, Kane C . Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev. 2010; 19(1):9-17. PMC: 2805474. DOI: 10.1158/1055-9965.EPI-09-0777. View

10.

Schroeck F, Aronson W, Presti Jr J, Terris M, Kane C, Amling C . Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?. BJU Int. 2008; 103(5):603-8. PMC: 2753544. DOI: 10.1111/j.1464-410X.2008.08118.x. View

11.

Hamilton R, Aronson W, Presti Jr J, Terris M, Kane C, Amling C . Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007; 110(10):2202-9. DOI: 10.1002/cncr.23012. View

12.

Jacinto A, Fede A, Fagundes L, Salvajoli J, Castilho M, Viani G . Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy. Radiat Oncol. 2007; 2:8. PMC: 1820601. DOI: 10.1186/1748-717X-2-8. View

13.

Teeter A, Banez L, Presti Jr J, Aronson W, Terris M, Kane C . What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol. 2008; 180(5):1980-4. PMC: 3182520. DOI: 10.1016/j.juro.2008.07.031. View

14.

Stephenson A, Scardino P, Kattan M, Pisansky T, Slawin K, Klein E . Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25(15):2035-41. PMC: 2670394. DOI: 10.1200/JCO.2006.08.9607. View

15.

Trapasso J, DeKernion J, Smith R, dOrey F . The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994; 152(5 Pt 2):1821-5. DOI: 10.1016/s0022-5347(17)32394-7. View

16.

Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P . Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007; 25(13):1765-71. DOI: 10.1200/JCO.2006.08.0572. View

17.

Stewart A, Scher H, Chen M, McLeod D, Carroll P, Moul J . Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005; 23(27):6556-60. DOI: 10.1200/JCO.2005.20.966. View

18.

Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P . Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294(4):433-9. DOI: 10.1001/jama.294.4.433. View

19.

Valicenti R, DeSilvio M, Hanks G, Porter A, Brereton H, Rosenthal S . Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys. 2006; 66(4):1064-71. DOI: 10.1016/j.ijrobp.2006.06.017. View